What is Omeros Corporation?
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.27B, and a P/E ratio of 14.3x.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.